CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.
Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这项文献计量分析系统描绘了胶质瘤免疫治疗研究的全球格局与新兴趋势。
胶质瘤是一种常见且致命的脑部恶性肿瘤,尽管现有治疗方法不断发展,患者预后仍较差,因此免疫疗法成为有前景的治疗策略。然而,目前尚无对胶质瘤免疫治疗研究趋势和热点的系统分析。本研究旨在通过文献计量学分析,阐明全球胶质瘤免疫治疗的研究趋势和知识结构。
从Web of Science核心合集数据库检索2000至2023年发表的胶质瘤免疫治疗相关文献。使用VOSviewer(1.6.18)、CiteSpace(5.7 R3)、Microsoft Charticulator和R语言Bibliometrix软件包等工具,定量分析并可视化研究趋势。
共纳入4,910篇文献。自2019年以来,年度发文量明显上升。美国在发文量和中心性方面居主导地位;《Frontiers in Immunology》发文最多;哈佛医学院机构发文量排名第一。Sampson, John H.博士是该领域发文最多的作者,共发表88篇、被引7,055次。《Clinical Cancer Research》总发文量及影响因子最高。关键词分析显示,免疫治疗、胶质母细胞瘤和临床试验是研究热点。肿瘤微环境、细胞死亡通路、嵌合抗原受体工程化、肿瘤相关巨噬细胞及纳武利尤单抗治疗提示胶质瘤免疫治疗未来方向正在发生变化。
本项文献计量分析系统描绘了胶质瘤免疫治疗研究的全球格局和新兴趋势,突出了CAR-T、程序性死亡受体1(PD-1)和纳武利尤单抗在当前研究中的重要性。人们对特定新抗原和预后肿瘤标志物日益关注,提示了未来潜在研究方向;此外,研究数据强调应加强国际合作,以推动该领域发展。
Glioma is a prevalent and lethal brain malignancy; despite current treatment options, the prognosis remains poor. Therefore, immunotherapy has emerged as a promising therapeutic strategy. However, research trends and hotspots in glioma immunotherapy have not been systematically analyzed. This study aimed to elucidate global research trends and knowledge structures regarding immunotherapy for glioma using bibliometric analysis.
Publications related to immunotherapy for glioma from 2000-2023 were retrieved from Web of Science Core Collection database (WoSCC). We conducted quantitative analysis and visualization of research trends using various tools, including VOSviewer (1.6.18), CiteSpace (5.7 R3), Microsoft Charticulator, and the Bibliometrix package in R.
A total of 4910 publications were included. The number of annual publications exhibited an obvious upward trend since 2019. The USA was the dominant country in terms of publication output and centrality. Frontiers in Immunology published the most articles. Harvard Medical School ranked first in productivity among institutions. Sampson, John H. Ph.D. is the most prolific author in the field with 88 articles and a total of 7055 citations. Clinical Cancer Research has the largest total number and impact factor. Analysis of keywords showed immunotherapy, glioblastoma, immunotherapy, and clinical trials as hot topics. The tumor microenvironment, cell death pathways, chimeric antigen receptor engineering, tumor-associated macrophages, and nivolumab treatment represent indicating shifts in the direction of future glioma immunotherapy development.
This bibliometric analysis systematically delineated global landscapes and emerging trends in glioma immunotherapy research. This study highlighted the prominence of Chimeric Antigen Receptor T-cell (CAR-T), Programmed Death-1 (PD-1), and nivolumab in current glioma immunotherapy research. The growing emphasis on specific neoantigens and prognostic tumor markers suggests potential avenues for future exploration. Furthermore, the data underscores the importance of strengthened international collaboration in advancing the field.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。